CTIX News 1.6700 07/25/2014 04:52:05 Cellceutix Corp (CTIX)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Cellceutix Corp (CTIX) 1.6700 $CTIX

Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - Pipeline Review, H1 2014
M2 - Tue Jul 15, 11:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/g486rc/methicillinsuscep) has announced the addition of the "Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - Dainippon Sumitomo Pharma Co., Ltd. - Immtech Pharmaceuticals, Inc. - Cellceutix Corporation - Lytix Biopharma AS - PharmaIN Corporation - ImmuVen, Inc. - Arsanis Biosciences GmbH For more information visit http://www.researchandmarkets.com/research/g4...llinsuscep

Cellceutix Announces Breakthrough in the Formulation of Its Novel Antibiotic Brilacidin(TM), Plans Studies to Treat Diabetic Foot Ulcers
Marketwire - Mon Jul 14, 6:00AM CDT
Cellceutix Corporation (OTCQB: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to announce that a significant breakthrough has been made in the formulation of Brilacidin(TM), Cellceutix's lead antibiotic in its portfolio of novel compounds called defensin mimetics. Previously, Brilacidin was stored in a refrigerated state. Cellceutix has stabilized the formulation of Brilacidin so that it is now stable at room temperature. This positions the Company to move forward with the immediate development of Brilacidin for the treatment of infected diabetic foot ulcers. Ophthalmic and otitic formulations will soon follow for ophthalmic and otitis media indications.

Cellceutix Anti-Fungal Compounds Awarded $1.5 Million SBIR Grant
Marketwire - Mon Jun 23, 6:01AM CDT
Cellceutix Corporation (OTCQB: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to announce that a research collaboration with Fox Chase Chemical Diversity Center ("FCCDC" (http://www.fc-cdci.com) has led to the award of a Phase 2B Small Business Innovation Research (SBIR) grant to FCCDC from the National Institute of Allergy and Infectious Disease (NIAID) of the National Institute of Health (NIH).

Autism - Pipeline Review, H1 2014 - 20 Companies & 42 Drug Profiles
M2 - Fri Jun 20, 2:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ltzhjv/autism_pipeline) has announced the addition of the "Autism - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Autism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Autism and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Dainippon Sumitomo Pharma Co., Ltd. - Novartis AG - Merz Pharma GmbH & Co. KgaA - Teva Pharmaceutical Industries Limited - Avanir Pharmaceuticals, Inc. - Snowdon Inc. - Curemark, LLC - Coronado Biosciences, Inc. - Omeros Corporation - Intra-Cellular Therapies, Inc. - Cellceutix Corporation - Heptares Therapeutics Ltd. - Otsuka Holdings Co., Ltd. - Reviva Pharmaceuticals Inc. - Naurex, Inc. - Nectid, Inc. - Mnemosyne Pharmaceuticals, Inc. - BioCrea GmbH - Saniona AB Drug Profiles - CM-AT - lurasidone hydrochloride - aripiprazole - cycloserine - fluoxetine - oxytocin - oxytocin - memantine hydrochloride - TSO - pioglitazone hydrochloride - oxytocin - oxytocin - (dextromethorphan hydrobromide quinidine sulfate) - oxytocin - oxytocin - RG-7314 - fluoxetine - fluoxetine - argipressin tannate - NU-211-01 NC-215-01 - Autologous Hematopoietic Stem Cells - glatiramer acetate - ITI-007 - Stem Cell Therapy for Central Nervous System Disorders - KM-391 - Program For Neurological Disorders - STX-110 - CN-2097 - acamprosate calcium - Small Molecules to Inhibit PI3K for Autism and Fragile X Syndrome For more information visit http://www.researchandmarkets.com/research/lt...m_pipeline

Cellceutix Clinical Trial of Anti-Cancer Drug Kevetrin Entering Eighth Cohort
Marketwire - Mon Jun 16, 6:01AM CDT
Cellceutix Corporation (OTCQB: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to report that the safety committee overseeing the Phase 1 clinical trial evaluating Cellceutix's lead anti-cancer drug Kevetrin for solid tumors being conducted at Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Center has approved dosing for the eighth cohort. The dosing was been increased approximately 33 percent from the seventh cohort to 215 mg/m2. Enrollment for the eighth cohort is expected to commence shortly.

Cellceutix Completes Patient Enrollment in Clinical Trial of Prurisol
Marketwire - Mon Jun 02, 6:01AM CDT
Cellceutix Corporation (OTCQB: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, reports today that patient enrollment has been completed in the Company's Phase 1 crossover study of its anti-psoriasis drug candidate Prurisol. Cellceutix expects lab results, pharmacokinetic studies, and analysis to take approximately two months. If the data shows bioequivalence of Prurisol with Abacavir Sulfate, the Company will then schedule a meeting with the U.S. Food and Drug Administration regarding initiating a Phase 2/3 trial of Prurisol through the 505(b)(2) regulatory pathway.

Osteoarthritis - Pipeline Review, H1 2014: Includes 50 Company Profiles
M2 - Thu May 29, 3:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/j5kb3t/osteoarthritis) has announced the addition of the "Osteoarthritis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Osteoarthritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Osteoarthritis and special features on late-stage and discontinued projects. The report features investigatory drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our team. Scope - The report provides a snapshot of the global therapeutic landscape of Osteoarthritis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Osteoarthritis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Osteoarthritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Mentioned: - A. Menarini Industrie Farmaceutiche Riunite Srl - AbbVie Inc. - Abiogen Pharma S.p.A. - Ablynx NV - AcurePharma AB - Addex Therapeutics - Allinky Biopharma - Ampio Pharmaceuticals, Inc. - Amura Holdings Ltd. - Asahi Kasei Pharma Corp. - Asklepios BioPharmaceutical, Inc. - Astellas Pharma Inc. - Aurigene Discovery Technologies Limited - Biopharm GmbH - Bone Medical Limited - Calzada Limited - Can-Fite BioPharma Ltd. - Cellceutix Corporation - Cellular Biomedicine Group, Inc. - Chong Kun Dang Pharmaceutical Corp. - Chugai Pharmaceutical Co., Ltd. - CrystalGenomics, Inc. - Galapagos NV - Genequine Biotherapeutics GmbH - Janssen Biotech, Inc. - Jenrin Discovery, Inc. - Laila Pharmaceuticals Pvt. Ltd. - MediPost Co., Ltd. - Medivir AB - Merck KGaA For more information visit http://www.researchandmarkets.com/research/j5...oarthritis

Cellceutix Signs Material Transfer Agreements for Defensin Mimetic Compounds With Leading Universities
Marketwire - Tue May 27, 6:01AM CDT
Cellceutix Corporation (OTCQB: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to report that the Company has signed material transfer agreements for compounds in its defensin mimetics portfolio with major university laboratories located in New York and New Jersey. These laboratories do significant government work and have expertise in anti-infective, anti-fungal and bio-defense applications. Cellceutix will be shipping the compounds to the university laboratories in the coming weeks. It is hoped that these collaborations will result in government assistance in developing the Company's novel compounds for a broad spectrum of indications.

Global Squamous Cell Carcinoma Therapeutics Pipeline Review 2014
M2 - Tue May 20, 9:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/72tfpz/squamous_cell) has announced the addition of the "Squamous Cell Carcinoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Squamous Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Squamous Cell Carcinoma and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Squamous Cell Carcinoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Squamous Cell Carcinoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Squamous Cell Carcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Squamous Cell Carcinoma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Boehringer Ingelheim GmbH - Novartis AG - Genmab A/S - Celgene Corporation - Clinuvel Pharmaceuticals Limited - Oncolytics Biotech Inc. - Oryzon Genomics S.A. - Hutchison MediPharma Limited - Merrimack Pharmaceuticals, Inc. - Neotropix, Inc. - Axelar AB - Onconova Therapeutics, Inc. - Omeros Corporation - Cellceutix Corporation - Cannabis Science, Inc. - Oncovir, Inc. - Genextra S.p.a. - Bexion Pharmaceuticals, LLC. - AbbVie Inc. Drug Profiles - afatinib - paclitaxel albumin-bound - AXL-1717 - pelareorep - rigosertib sodium - afamelanotide - boanmycin hydrochloride [docetaxel] - CIGB-128 - DAC-0060 - Poly-ICLC - BYL-719 - LJM-716 - interleukin-15 - Antibody Drug Conjugate for Squamous Cell Tumor - irinotecan sucrosofate liposomal - Kevetrin - CUV-9900 - BXQ-350 - CS-TATI-1 - CS-S/BCC-1 - TF-011-Monomethyl Auristatin E - AMXT-1501 eflornithine - Allogenic Mesenchymal Stem Cells - HMPL-453 - NTX-500 - GPR87 Antagonist for Cancer - GPR39 Antagonist for Esophageal Squamous Cell Carcinoma and Obesity-Related Type-2 Diabetes - Monoclonal Antibody For Squamous Cell Cancer - Drugs for Cutaneous Squamous Cell Carcinoma (cSCC) For more information visit http://www.researchandmarkets.com/research/72...amous_cell

Cellceutix Plans for Entry in Diabetic Foot Wound and Ulcer Market
Marketwire - Mon May 19, 6:01AM CDT
Cellceutix Corporation (OTCQB: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to report that its lead antibiotic, Brilacidin(TM), demonstrated visually convincing wound healing properties in a recently completed experiment in a diabetic rat model.

Cellceutix Comments on Positive FDA Advisory Vote for Dalbavancin and Tedizolid
Marketwire - Tue Apr 01, 7:04AM CDT
Cellceutix Corporation (OTCQB: CTIX) (the "Company" is pleased to comment to its shareholders on yesterday's exciting regulatory developments and how it impacts Cellceutix's drug, Brilacidin.

Cellceutix Reports 20 Percent Enrollment Completed in Phase 2b Trial of Brilacidin as Short-Course Therapy for ABSSSI
Marketwire - Mon Mar 31, 8:25AM CDT
Cellceutix Corporation (OTCQB: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to provide shareholders an update on the status of the Company's clinical trial of its novel antibiotic Brilacidin as a treatment for Acute Bacterial Skin and Skin Structure Infections (ABSSSI). One month into the study, the trial has completed enrollment of approximately 20 percent of the total patients scheduled in the protocol.

Cellceutix Initiates Clinical Trial of Prurisol as New Treatment for Psoriasis
Marketwire - Tue Mar 25, 5:01AM CDT
Cellceutix Corporation (OTCQB: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to announce the initiation of the Company's clinical trial of its oral, small molecule drug candidate Prurisol(TM) for the treatment of psoriasis. The Prurisol(TM) tablets have been delivered to the clinical site in Miami, Florida and screening of subjects can now begin with the first dosing expected in the coming days.

Cellceutix to Initiate Psoriasis Clinical Trial
Marketwire - Fri Mar 21, 5:00AM CDT
Cellceutix Corporation (OTCQB: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, announces today that the U.S. Food and Drug Administration's ("FDA" 30-day waiting period pertaining to the Company's Investigational New Drug Application ("IND" for Prurisol(TM) has now passed. Cellceutix is moving towards the commencement of clinical trials of Prurisol(TM) as a new drug candidate for the treatment of psoriasis.

Seventh Cohort Underway in Cellceutix Clinical Trial of Kevetrin for Solid Tumors
Marketwire - Wed Mar 19, 7:42AM CDT
Cellceutix Corporation (OTCQB: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, announces today that the seventh cohort is now in progress in the Company's ongoing Phase 1 clinical trial of Kevetrin(TM), Cellceutix's novel anti-cancer drug candidate.

Cellceutix Reports 14 Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Patients Treated in Phase 2b Clinical Trial
Marketwire - Mon Mar 10, 5:01AM CDT
Cellceutix Corporation (OTCQB: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, announces today that through March 7 a total of 14 patients have been treated in the Company's Phase 2b clinical (7% of the 200 patients to be treated). The multi-center study is evaluating the safety and efficacy of Brilacidin as a novel antibiotic drug candidate as compared to daptomycin for the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI). Patients are receiving one of three different dosing regimens of Brilacidin (one of two single-dose regimens or one 3-day regimen) or a 7-day regimen of daptomycin. Cellceutix is pleased with the initial enrollment pace and believes that it will continue to escalate as the trial moves forward.

Cellceutix Expands to Gram-Negative Bacterial Infections
Marketwire - Wed Mar 05, 5:00AM CST
Cellceutix Corporation (OTCQB: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to inform shareholders that several preclinical investigations are underway with several lead compounds in animal models of Gram-negative bacterial infections. The Company is focusing this research on some of the most difficult to treat multi-drug resistant or "pandrug-resistant" bacterium where there is a significant and growing medical need for new therapies.

Cellceutix Enrolls First Patients in Phase 2b ABSSSI Clinical Trial
Marketwire - Wed Feb 26, 5:00AM CST
Cellceutix Corporation (OTCQB: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, announces today that the first patients have been enrolled and treated in the Company's Phase 2b clinical trial of Brilacidin in patients with Acute Bacterial Skin and Skin Structure Infection (ABSSSI).

Cellceutix Selects Dr. Reddy's Laboratories for Formulation of Brilacidin for Ophthalmic and Otitis Infections
Marketwire - Mon Feb 24, 6:01AM CST
Cellceutix Corporation (OTCQB: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, announces today that the Company has concluded negotiations with formulation developers and selected Dr. Reddy's Custom Pharmaceutical Services (CPS), part of the Pharmaceutical Services and Active Ingredients (PSAI) business unit of Dr. Reddy's Laboratories Ltd. ("Dr. Reddy's" , a New York Stock Exchange-listed company traded under the ticker "RDY", for the formulation of the Company's defensin mimetic drug Brilacidin for use in ophthalmic and otitis infections.

Cellceutix Submits Investigational New Drug Application (IND) for Clinical Trial of New Anti-Psoriasis Drug, Enrollment Underway in Phase 2b Clinical Trials of Brilacidin
Marketwire - Tue Feb 18, 6:01AM CST
Cellceutix Corporation (OTCQB: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, announces today that the Company has submitted an Investigational New Drug Application ("IND" to the U.S. Food and Drug Administration ("FDA" for the clinical development of Prurisol as a potential new treatment for psoriasis.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

AR Cards in Casino Gaming: A High-Stakes Revolution

Updated Category News Views 13

A New Breed of Casino Experience Walk into a casino today, and you might just enter a whole new reality. No, this isn’t a cheesy magician’s trick or a glitzy PR stunt—this is the real deal brought to you by augmented reality (AR) trading cards. Imagine the slots you love wrapped in a sci-fi movie where characters leap out, tap you on the shoulder, and call you by...

Continue Reading
Nevada Expands Rural Youth Mental Health Access

Updated Category News Views 148

Nevada's Rural Mental Health Crisis When you're navigating the barren stretches of rural Nevada, the scenic views can be breathtaking. But for many families, finding basic services like mental health care is as challenging as striking water in the desert. Cartwheel Care has taken the bull by the horns with their latest initiative to bridge this glaring gap. Partnering...

Continue Reading
HKEX Unveils New Offshore RMB Bond Index

Updated Category News Views 221

Here's the scoop: Hong Kong Exchanges and Clearing Limited (HKEX) just rolled out something worth eyeing—the HKEX Offshore RMB Bond Index. It's the first of its kind from HKEX, catered to those Dim Sum bonds floating around in the city. With Bloomberg lending a hand on the index smarts, this step is poised to give Hong Kong a leg up in the global financial marathon....

Continue Reading
Akeso's Gumokimab Wins NMPA Approval for AS Treatment

Updated Category News Views 199

Gumokimab Approved: A New Dawn in AS Treatment Yeah, the biotech world shifts gears today as Akeso's gumokimab received the green light from China's National Medical Products Administration (NMPA). This approval for treating ankylosing spondylitis, or AS, isn't just another checkbox for Akeso; it's a game-changer in tackling this chronic inflammatory disease. Why should...

Continue Reading
Lululemon Faces Class Action over Alleged Missteps

Updated Category News Views 39

Trouble Brewing for Lululemon Y'ever get that gut feeling when something doesn't smell right? Well, Lululemon Athletica (NASDAQ: LULU) investors are probably feeling that now. A class action's kicking up dust over what some are saying was a downright bumpy ride. The brainiacs at Robbins LLP urge those who've lost bucks riding the LULU train to step forward ahead of the...

Continue Reading
Exploring Creation: A Fresh Look at Genesis

Updated Category News Views 67

Opening Up Genesis in a New Light Hey, if you’re like most folks, you’ve probably heard Genesis framed as the battleground for science versus religion debates, right? Enter into this mix a fresh take with Robert E. Franzen’s new book, The Narration of Creation. This book asks you to overlook those grand philosophical fights and instead focus on the narrative itself....

Continue Reading
Pollo AI Unveils York AI: Automating Social Growth

Updated Category News Views 278

York AI Debuts as the New Kid on the Block Amid the hustle and bustle of a tech-savvy Singapore, Pollo AI’s latest offering, York AI, sashays onto the scene with the promise of putting social media growth on cruise control. We're talking about a digital sidekick that seems to know your online persona better than you do. It’s tailored for everyone from the small-time...

Continue Reading
AdMaven's Mave AI: Revolutionizing Campaign Management

Updated Category News Views 106

Taking the Tedious Out of Advertising You've got to love it when technology actually makes life easier, rather than more complicated. AdMaven's latest fancy toy, the AI assistant Mave, is promising just that. It's designed to take the heavy lifting off advertisers' shoulders, especially the day-to-day grind of tweaking ad settings and monitoring performance. If you've...

Continue Reading
Portillo's Faces Legal Heat: Investor Class Action Filed

Updated Category News Views 53

What’s Eating Portillo's? Ah, once upon a misstep in the land of promising expansion, now we have Portillo's Inc. (NASDAQ: PTLO) neck-deep in legal hot water. Those golden fries and famous sandwiches somehow didn't pave the way for stockholder bliss. Why the turmoil? On an ordinary November morning, the DJS Law Group made it clear: They're rallying the troops for a...

Continue Reading
Trades Workforce Shortage Costs Wallop U.S. Economy

Updated Category News Views 83

The Forgotten Backbone of America Don't sleep on this: America's got itself a trade worker crisis, and it's not just a numerical hiccup. We’re down nearly 1.9 million skilled trades workers, and that's a gut punch to the economy—a hefty $1.2 billion a day in GDP loss. These are the folks who keep the wheels greased, the lights on, and the goods flowing. Without them,...

Continue Reading

Top 5 Most Recently Viewed Articles

US Agriculture Partners with CeresAI for Enhanced Farming Insights

Updated Category News Views 168

US Agriculture and CeresAI: A Groundbreaking Collaboration In an innovative move, US Agriculture, LLC has teamed up with CeresAI to transform farmland monitoring through advanced technology. This partnership aims to leverage artificial intelligence for improved performance in agricultural investments by optimizing farmland management and reducing costs associated with...

Continue Reading
Infosys Launches New Zurich Office to Drive AI Innovations

Updated Category News Views 175

Infosys Expands Its Zurich Office for Enhanced Client Collaboration Infosys, a global trailblazer in digital services and consulting, has inaugurated its new office in Zurich, Switzerland, marking a pivotal moment in its 25-year journey within the Swiss market. With this move, Infosys not only relocates its Swiss headquarters to The Circle at Zurich Airport but also...

Continue Reading
SierraConstellation Partners Celebrates Significant Award Wins

Updated Category News Views 117

A Major Milestone for SierraConstellation Partners SierraConstellation Partners (“SCP”), a foremost interim management and advisory firm, has received several prestigious awards for its outstanding work in business restructuring. The Global M&A Network has recognized SCP's exemplary handling of both the sale of Vyera Pharmaceuticals' assets and the reorganization of...

Continue Reading
Kaltura's AI Innovations Recognized in Market Guide

Updated Category News Views 179

Kaltura's Recognition in the Industry Kaltura, a leader in AI Video Experience Cloud technology, has recently been acknowledged as a Representative Vendor in the Gartner Market Guide for Video Platform Services. This recognition is a testament to Kaltura's forward-thinking approach and its commitment to enhancing enterprise video solutions. The Importance of Video...

Continue Reading
Liberty Gold’s Annual Meeting Outcomes: New Leadership and Directions

Updated Category News Views 288

Liberty Gold Announces Annual General Meeting Results Vancouver, British Columbia – Liberty Gold Corp. (TSX: LGD; OTCQX: LGDTF) has shared the outcomes of its recent Annual General Meeting (AGM) where shareholders participated in crucial decisions shaping the future leadership of the company. The AGM marked a significant moment for Liberty Gold as it transitions into a...

Continue Reading